Ascendis Pharma A/S

ASND

Market cap $13.4B

Ascendis Pharma is initiated with a buy rating, reflecting its transition to a durable, commercial-stage rare endocrine franchise. ASND's valuation premium is justified by high-quality revenue growth, multiple product launches, operating leverage, and reduced financing risk. Yorvipath and Yuviwel are driving robust pipeline momentum, with Yorvipath scaling rapidly in chronic hypoparathyroidism and Yuviwel poised for expansion in achondroplasia.

Ascendis Pharma A/S (ASND) Q1 2026 Earnings Call Transcript

- Q1 2026 revenue of €197 million for YORVIPATH ® and €44 million for SKYTROFA ® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL ® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH are cementing our position as a leading global biopharma,” said Jan Mikkelsen, President and Chief Executive Officer of Ascendis Pharma.

COPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated with once-weekly TransCon CNP (navepegritide) in its pivotal ApproaCH Trial demonstrated significantly greater annualized growth velocity (AGV) compared to placebo at Week 52, and sustained these growth improvements through up to two years of treatment. The safety profile for this subgroup through up to two years of treatment was similar to the overall population, with a low rate of injection site reactions (ISRs, all mild), no symptomatic hypotension, and no acceleration of bone age. The data follow previously reported Week 104 results showing consistent improvements in growth and body proportionality in the overall population, and expand on data recently presented by M. Jennifer Abuzzahab, M.D. during PES 2026, the annual meeting of the Pediatric Endocrine Society.

COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on May 7, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results.

The market's focus on Microsoft's cloud computing platform Azure, growth and concerns around rising competition in artificial intelligence drove shares lower. Shares of Adyen declined as the company posted slower-than-expected revenue growth. We eliminated our stake in payroll software provider Paylocity. The stock has suffered amid the market sell-off of enterprise software companies.

COPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior Notes due 2028 (the “notes”) (CUSIP No. 04351P AD3 / ISIN No. US04351PAD33) for redemption on May 6, 2026 (the “Redemption Date”). Ascendis' redemption right in respect of the notes arises pursuant to Section 4.03(B) of the indenture (the “Indenture”), dated as of March 29, 2022, between Ascendis and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as a result of the last reported sale price per ordinary share having exceeded 130% of the conversion price on each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on, and including, April 21, 2026.

COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares (ADSs). The ordinary shares trade under the same ticker symbol “ASND” as previously used for the ADS listing.

- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs)  - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held  - Simplified listing structure intended to enable enhanced depth and breadth of ownership COPENHAGEN, Denmark, April 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it plans to list its ordinary shares directly on Nasdaq, effective at the opening of trading on April 20, 2026. As part of the transition to a direct listing of ordinary shares on The Nasdaq Global Select Market, all outstanding ADSs will be exchanged for ordinary shares.

- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community